Loading…
NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus
Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to exam...
Saved in:
Published in: | Medical oncology (Northwood, London, England) London, England), 2014-01, Vol.31 (1), p.796-796, Article 796 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553 |
---|---|
cites | cdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553 |
container_end_page | 796 |
container_issue | 1 |
container_start_page | 796 |
container_title | Medical oncology (Northwood, London, England) |
container_volume | 31 |
creator | Yan, Hongjiang Wang, Renben Jiang, Shumei Zhu, Kunli Feng, Rui Xu, Xiaoqing Meng, Xiangjiao |
description | Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively (
P
= 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment (
P
= 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels (
P
= 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS (
P
= 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC. |
doi_str_mv | 10.1007/s12032-013-0796-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1465861097</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1465861097</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</originalsourceid><addsrcrecordid>eNp1kUtr3DAUhUVJaB7tD-gmCLLpxs3Vy7KXIaRNIDSLttCdkK3rGYWx5Uh2YP595M40hEA2utLVd48OOoR8YfCNAeiLxDgIXgATBei6LOADOWZK1QUT7O9B3gulC1AlHJGTlB4AOFO8_kiOuBSghdTHxP38dU1bO9AxovPtRKc10oRD8pN_8tOWToE67PywnJG2a-xDtM6HzEU7bmnoaOrtZkNbXBYbWz-E3i59TGFc29WcPpHDzm4Sft7XU_Ln-_Xvq5vi7v7H7dXlXdFKUU2FlAqBd7Jz2XPTlKLiupKVc9ZWqpKK8Ua2GsE6yxuoQQnNupqja5SQjVLilHzd6Y4xPM6YJtP7tPiyA4Y5GSZLVZUMap3R8zfoQ5jjkN1lSivgWv8TZDuqjSGliJ0Zo-9t3BoGZonA7CIwOQKzRGAgz5ztleemR_cy8f_PM8B3QMpXwwrjq6ffVX0G0jGQ9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1475027755</pqid></control><display><type>article</type><title>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</title><source>Springer Link</source><creator>Yan, Hongjiang ; Wang, Renben ; Jiang, Shumei ; Zhu, Kunli ; Feng, Rui ; Xu, Xiaoqing ; Meng, Xiangjiao</creator><creatorcontrib>Yan, Hongjiang ; Wang, Renben ; Jiang, Shumei ; Zhu, Kunli ; Feng, Rui ; Xu, Xiaoqing ; Meng, Xiangjiao</creatorcontrib><description>Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively (
P
= 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment (
P
= 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels (
P
= 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS (
P
= 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-013-0796-0</identifier><identifier>PMID: 24307347</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Aged ; Antigens, Neoplasm - blood ; Biomarkers, Tumor - blood ; Carcinoembryonic Antigen - blood ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - radiotherapy ; Chemoradiotherapy - methods ; Cisplatin - administration & dosage ; Endosonography ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - radiotherapy ; Etoposide - administration & dosage ; Female ; Hematology ; Humans ; Internal Medicine ; Keratin-19 - blood ; Lymphatic Metastasis ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Phosphopyruvate Hydratase - blood ; Positron-Emission Tomography ; Predictive Value of Tests ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Medical oncology (Northwood, London, England), 2014-01, Vol.31 (1), p.796-796, Article 796</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</citedby><cites>FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24307347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><creatorcontrib>Xu, Xiaoqing</creatorcontrib><creatorcontrib>Meng, Xiangjiao</creatorcontrib><title>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively (
P
= 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment (
P
= 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels (
P
= 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS (
P
= 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.</description><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Chemoradiotherapy - methods</subject><subject>Cisplatin - administration & dosage</subject><subject>Endosonography</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - radiotherapy</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Keratin-19 - blood</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Phosphopyruvate Hydratase - blood</subject><subject>Positron-Emission Tomography</subject><subject>Predictive Value of Tests</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kUtr3DAUhUVJaB7tD-gmCLLpxs3Vy7KXIaRNIDSLttCdkK3rGYWx5Uh2YP595M40hEA2utLVd48OOoR8YfCNAeiLxDgIXgATBei6LOADOWZK1QUT7O9B3gulC1AlHJGTlB4AOFO8_kiOuBSghdTHxP38dU1bO9AxovPtRKc10oRD8pN_8tOWToE67PywnJG2a-xDtM6HzEU7bmnoaOrtZkNbXBYbWz-E3i59TGFc29WcPpHDzm4Sft7XU_Ln-_Xvq5vi7v7H7dXlXdFKUU2FlAqBd7Jz2XPTlKLiupKVc9ZWqpKK8Ua2GsE6yxuoQQnNupqja5SQjVLilHzd6Y4xPM6YJtP7tPiyA4Y5GSZLVZUMap3R8zfoQ5jjkN1lSivgWv8TZDuqjSGliJ0Zo-9t3BoGZonA7CIwOQKzRGAgz5ztleemR_cy8f_PM8B3QMpXwwrjq6ffVX0G0jGQ9A</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Yan, Hongjiang</creator><creator>Wang, Renben</creator><creator>Jiang, Shumei</creator><creator>Zhu, Kunli</creator><creator>Feng, Rui</creator><creator>Xu, Xiaoqing</creator><creator>Meng, Xiangjiao</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140101</creationdate><title>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</title><author>Yan, Hongjiang ; Wang, Renben ; Jiang, Shumei ; Zhu, Kunli ; Feng, Rui ; Xu, Xiaoqing ; Meng, Xiangjiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Chemoradiotherapy - methods</topic><topic>Cisplatin - administration & dosage</topic><topic>Endosonography</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - radiotherapy</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Keratin-19 - blood</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Phosphopyruvate Hydratase - blood</topic><topic>Positron-Emission Tomography</topic><topic>Predictive Value of Tests</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><creatorcontrib>Xu, Xiaoqing</creatorcontrib><creatorcontrib>Meng, Xiangjiao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Hongjiang</au><au>Wang, Renben</au><au>Jiang, Shumei</au><au>Zhu, Kunli</au><au>Feng, Rui</au><au>Xu, Xiaoqing</au><au>Meng, Xiangjiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>31</volume><issue>1</issue><spage>796</spage><epage>796</epage><pages>796-796</pages><artnum>796</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively (
P
= 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment (
P
= 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels (
P
= 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS (
P
= 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24307347</pmid><doi>10.1007/s12032-013-0796-0</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1357-0560 |
ispartof | Medical oncology (Northwood, London, England), 2014-01, Vol.31 (1), p.796-796, Article 796 |
issn | 1357-0560 1559-131X |
language | eng |
recordid | cdi_proquest_miscellaneous_1465861097 |
source | Springer Link |
subjects | Aged Antigens, Neoplasm - blood Biomarkers, Tumor - blood Carcinoembryonic Antigen - blood Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - radiotherapy Chemoradiotherapy - methods Cisplatin - administration & dosage Endosonography Esophageal Neoplasms - drug therapy Esophageal Neoplasms - radiotherapy Etoposide - administration & dosage Female Hematology Humans Internal Medicine Keratin-19 - blood Lymphatic Metastasis Male Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pathology Phosphopyruvate Hydratase - blood Positron-Emission Tomography Predictive Value of Tests Tomography, X-Ray Computed Treatment Outcome |
title | NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A59%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NSE%20can%20predict%20the%20sensitivity%20to%20definitive%20chemoradiotherapy%20of%20small%20cell%20carcinoma%20of%20esophagus&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Yan,%20Hongjiang&rft.date=2014-01-01&rft.volume=31&rft.issue=1&rft.spage=796&rft.epage=796&rft.pages=796-796&rft.artnum=796&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-013-0796-0&rft_dat=%3Cproquest_cross%3E1465861097%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1475027755&rft_id=info:pmid/24307347&rfr_iscdi=true |